Comparison

ArthritoMab™ vs. Competitor cocktail

Scientists have realized that the ArthritoMab™ Antibody cocktail provides a steady and controlled disease progression that is consistent from batch to batch. Other cocktails produce such a rapid and severe disease thereby limiting drug treatment schedules or requiring early termination of a study.

*Each lab must optimize the protocol. These figures are based on standard recommended protocols and quantity of cocktail provided per vial

CAIA model vs CIA model

The CIA model is a 6 week study that is unsynchronized. Since the disease is unsynchronized, it can take nearly 2 weeks for all animals to begin to exhibit symptoms making therapeutic treatment schedules more challenging. The length of the study blocks vivarium space longer and requires more weekends spent in the lab. There is also a substantial increase in the labor due to far more drug administrations and scoring and measurement periods as well as an increase in the amount of precious compound required. The CAIA model cuts all of this down to just 2 weeks and produces comparable results even at the histological level.

CAIA model vs K/BxN

The K/BxN model runs on a similar principle in that it uses auto-antibodies from sera of K/BxN strains that are transferred to recipient animals to induce RA. The mechanisms of action, severity and study length are similar in each model. The K/BxN however requires labs to maintain the expensive colonies that are the source of the polyclonal mixture, which can vary batch to batch. This also produces concerns over maintaining the colony, waiting for the animals to reach a certain age prior to harvesting the sera and how to handle colonies that go down due to sickness or contamination. The ArthritoMab™ Antibody Cocktail eliminates all of these issues by providing a cocktail of anti-CII antibodies that are readily available and are consistent from batch to batch.